A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients with Esophageal Adenocarcinoma.
Alexander J ByunRachel A GrosserJennie K ChoeNabil P RizkLaura H TangDaniela MolenaKay See TanDavid RestleWaseem CheemaAmy ZhuHans GerdesArnold J MarkowitzManjit S BainsValerie W RuschDavid R JonesPrasad S AdusumilliPublished in: Annals of surgery (2023)
Pre-treatment tumor mesothelin expression is prognostic of OS for patients with locally advanced esophageal ADC, whereas serum SMRP is not a reliable biomarker for monitoring treatment response or recurrence.
Keyphrases
- locally advanced
- clinical trial
- squamous cell carcinoma
- rectal cancer
- poor prognosis
- neoadjuvant chemotherapy
- radiation therapy
- phase ii study
- study protocol
- open label
- magnetic resonance imaging
- randomized controlled trial
- long non coding rna
- computed tomography
- free survival
- lymph node
- binding protein
- diffusion weighted imaging
- smoking cessation